| This article has been cited by |
| 1 | | |
| Rosa Isela García-Ríos,Armando Mora-Pérez,Cesar Soria-Fregozo |
| .2017;() |
| [DOI] |
|
| 2 | Autophagy and glycolysis independently attenuate silibinin-induced apoptosis in human hepatocarcinoma HepG2 and Hep3B cells | |
| J Yang,Y Sun,F Xu,W Liu,T Hayashi,K Mizuno,S Hattori,H Fujisaki,T Ikejima |
| Human & Experimental Toxicology.2021;40(12)2048 |
| [DOI] |
|
| 3 | Serotonin Receptor 5-HT2A Regulates TrkB Receptor Function in Heteroreceptor Complexes | |
| Tatiana Ilchibaeva,Anton Tsybko,Andre Zeug,Franziska E. Müller,Daria Guseva,Stephan Bischoff,Evgeni Ponimaskin,Vladimir Naumenko |
| Cells.2022;11(15)2384 |
| [DOI] |
|
| 4 | Zinc Deficiency Blunts the Effectiveness of Antidepressants in the Olfactory Bulbectomy Model of Depression in Rats | |
| Anna Rafalo-Ulinska,Bartlomiej Pochwat,Paulina Misztak,Ryszard Bugno,Agata Kryczyk-Poprawa,Wlodzimierz Opoka,Bozena Muszynska,Ewa Poleszak,Gabriel Nowak,Bernadeta Szewczyk |
| Nutrients.2022;14(13)2746 |
| [DOI] |
|
| 5 | A synopsis of drugs currently in preclinical and early clinical development for the treatment of benign prostatic hyperplasia | |
| Kanika Gupta,Mona Yezdani,Tiffany Sotelo,Jeanny B Aragon-Ching |
| Expert Opinion on Investigational Drugs.2015;24(8)1059 |
| [DOI] |
|
| 6 | A synopsis of drugs currently in preclinical and early clinical development for the treatment of benign prostatic hyperplasia | |
| Minal Jaggar,Vidita A. Vaidya |
| Expert Opinion on Investigational Drugs.2018;24(8)395 |
| [DOI] |
|
| 7 | A synopsis of drugs currently in preclinical and early clinical development for the treatment of benign prostatic hyperplasia | |
| Berend Olivier |
| Expert Opinion on Investigational Drugs.2019;24(8)395 |
| [DOI] |
|
| 8 | A synopsis of drugs currently in preclinical and early clinical development for the treatment of benign prostatic hyperplasia | |
| Michelle Roche,John P. Kelly |
| Expert Opinion on Investigational Drugs.2023;190(8)43 |
| [DOI] |
|
